The abacavir hypersensitivity reaction: A review

Clinical Therapeutics

Volumn 24, Issue 10, 2002, Pages 1502-1514

  Clay, Patrick G ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abacavir; Antiretrovirals; Efficacy; HIV AIDS; Hypersensitivity; Safety

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; PENICILLIN DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; AGRANULOCYTOSIS; ANAPHYLAXIS; COUGHING; DEATH; DIARRHEA; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPOTENSION; INCIDENCE; KIDNEY FAILURE; LETHARGY; MALAISE; MALE; MOUTH LESION; MYALGIA; NAUSEA; NEUTROPENIA; PATIENT EDUCATION; PHARYNX DISEASE; RASH; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; STEVENS JOHNSON SYNDROME; SYMPTOMATOLOGY; TACHYCARDIA; TACHYPNEA; THROAT DISEASE; VOMITING; WHEEZING;

EID: 0036811774     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80057-1     Document Type: Review

References (48)

1. Pallela FJ Jr, Delaney KM, Moorman AC, et al, for the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Spira R, Marimoutou C, Binquet C, et al, for the Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France 1995-1997. J Acquired Immune Defic Syndr Hum Retrovirol. 1998;18:358-364.
3. Correll PK, Law MG, McDonald AM, et al. HIV disease progression in Australia in the time of combination antiretroviral combination therapies. Med J Aust. 1998; 169:469-472.
4. Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS. 1997;11:1731-1738.
5. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 2000;13:no. 1. Available at: http://www. cdc.gov/hiv/stats/hasr1301.htm. Accessed July 20, 2002.
6. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135:17-26.
7. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-823.
8. Freedberg FA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824-831.
9. Dever LL, Oruwari PA, Figueroa WE, et al. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. Ann Pharmacother. 2000;34:580-584.
10. Hardy H, Esch LD, Morse GD. Glucose disorders associated with HIV and its drug therapy. Ann Pharmacother. 2001;35:343-351.
11. Gangar M, Arias G, O'Brien JG, Kemper CA. Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. Ann Pharmacother. 2000;34:839-842.
12. d'Arminio Monforte A, Testa L, Gianotto M, et al. Indinavir-related alopecia. AIDS. 1998;12:328. Letter.
13. Manfredi R, Calza L, Chiodo F. Gynecomastia associated with highly active antiretroviral therapy. Ann Pharmacother. 2001;35:438-439.
14. Martinez E, Garcia-Viejo MA, Blanch L, Gatell JM. Lipodystrophy syndrome in patients with HIV infection: Quality of life issues. Drug Saf. 2001;24:157-166.
15. Ziagen® [package insert]. Research Triagle Park, NC: GlaxoSmithKline; 2000.
16. Foster RH, Faulds D. Abacavir. Drugs. 1998;55:729-736.
17. Hervey PS, Perry CM. Abacavir: A review of its clinical potential in patients with HIV infection. Drugs. 2000;60:447-479.
18. Faletto MB, Miller WH, Garvey EP, et al. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother. 1997;41:1099-1107.
19. Stein DS, Moore KP. Phosphorylation of nucleoside analog antiretrovirals: A review for clinicians. Pharmacotherapy. 2001;21:11-34.
20. Chittick GE, Gillotin C, McDowell JA, et al. Abacavir: Absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy. 1999;19:932-942.
21. McDowell JA, Chittick GE, Stevens CP, et al. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2000;44:1686-1690.
22. Harrigan PR, Stone C, Griffin P, et al, for the CNA 2001 Investigative Group. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. J Infect Dis. 2000;181:912-920.
23. Masquelier B, Race E, Tamalet C, et al. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): Multicenter study of patients treated with RT inhibitors. Antimicrob Agents Chemother. 2001;45:1836-1842.
24. Van Laethem K, Witvrouw M, Balzarani J, et al. Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. AIDS. 2000;14:469-471.
25. Funk ML, White AD, Cutrell A, et al. Life expectancy of patients with advanced HIV/AIDS enrolled in the abacavir expanded access program. Poster presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Can. Poster 2042.
26. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother. 1997;41:1094-1098.
27. Abraham PE, Sorensen SJ, Baker WH, Cushing HE. Nelfinavir desensitization. Ann Pharmacother. 2001;35:553-556.
28. Arnold PA, Guglielmo BJ, Hollander H. Severe hypersensitivity reaction upon rechallenge with trimethoprim-sulfamethoxazole in a patient with AIDS. Drug Intell Clin Pharm. 1988;22:43-45.
29. Myers KW, Katial RK, Engler RJ. Probenicid hypersensitivity in AIDS: A case report. Ann Allergy Asthma Immunol. 1998;80:416-418.
30. Walensky RP, Goldberg JH, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS. 1999;13:999-1000.
31. Escaut L, Liotier JY, Albengres E, et al. Abacavir rechallenge has to be avoided in a case of hypersensitivity reaction. AIDS. 1999;13:1419-1420.
32. Shapiro M, Ward KM, Stern JJ. A near-fatal hypersensitivity reaction to abacavir: Case report and review of the literature. AIDS Read. 2001;11:222-226.
33. Frissen PH, de Vries J, Weigel HM, Brinkman K. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. AIDS. 2001; 15:289. Letter.
34. Easterbrook PJ, King D, Waters A, et al. Epidemiological risk factors and immunological mechanisms of hypersensitivity reactions to abacavir. Poster presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, III. Poster 621.
35. Hetherington SV, Steel H, Naderer O, et al. Hypersensitivity reactions during therapy with abacavir: Analysis of 636 cases for clinical presentation and risk factors. Poster presented at: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Poster 60.
36. Thompson M, Shaefer MS, Williams V, et al. Interruptions in abacavir dosing are not associated with increased risk of hypersensitivity in the HEART study (NZT4006). In: Program and Abstracts of 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Can. Abstract L-14.
37. ®. Research Triangle Park, NC: GlaxoSmithKline; January 2000.
38. Delves PJ, Roitt IM. The immune system: First of two parts. N Engl J Med. 2000; 343:37-49.
39. Delves PJ, Roitt IM. The immune system: Second of two parts. N Engl J Med. 2000; 343:108-117.
40. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med. 2001; 344:30-37.
41. Kay AB. Allergy and allergic diseases. Second of two parts. N Engl J Med. 2001; 344:109-113.
42. Clay PG, Rathbun RC, Slater LN. Management protocol for abacavir-related hypersensitivity reaction. Ann Pharmacother. 2000;34:247-249.
43. Shelburne SA III, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: Emergence of a unique syndrome during highly active antiretroviral therapy. Medicine. 2002;81:213-227.
44. Loeliger AE, Steel H, McGuirk S, et al. The abacavir hypersensitivity reaction and interruptions in therapy. AIDS. 2001;15:1325-1326.
45. Modest GA, Fuller J. Abacavir and diabetes. N Engl J Med. 2001;344:142-143. Letter.
46. Hetherington SV, Lenhard JM, Powell GS. Abacavir and diabetes - A reply. N Engl J Med. 2001;343:143-144. Letter.
47. Tikhomirov V, Namek K, Hindes R. Agranulocytosis induced by abacavir. AIDS. 1999;13:1420-1421.
48. Saag MS, Sonnerborg A, Torres RA, et al, for the Abacavir Phase 2 Clinical Team. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. AIDS. 1998; 12:F203-F209.